Problem. A Chinese innovative drug development company intended to determine the optimal crystal form of a drug candidate in its pipeline within two months, in order to control the risk associated with form selection for the clinical studies. Traditional experimental methods could not meet the customer’s strict requirements on the study quality due to the stringent timeline.
Solution. We conducted a complete solid form risk assessment within 37 days by combining CSP and wet lab experimentation to identify and validate the most ideal crystal form pursuant to the customer’s needs.
Result. The figure below depicts the timeline and milestones of this project. Our CSP not only identified potential polymorphs, but also guided the experimental screening. Our CSP predicted three potential stable crystal forms within two weeks, which informed the experimental screening to search for one crystal form that might otherwise be missed. The results were eventually validated by wet lab experimentation. Crystal form I was selected as the preferred medicinal form because it is the most thermodynamically stable polymorph, as reflected by its lowest relative free energy at both 0K and 300K.